The present invention relates generally to medical devices used for visualizing and/or assessing regions of tissue within a body. More particularly, the present invention relates to methods and apparatus for visualizing and/or assessing regions of tissue within a body, such as the chambers of a heart, to facilitate diagnoses and/or treatments for the tissue.
Conventional devices for visualizing interior regions of a body lumen are known. For example, ultrasound devices have been used to produce images from within a body in vivo. Ultrasound has been used both with and without contrast agents, which typically enhance ultrasound-derived images.
Other conventional methods have utilized catheters or probes having position sensors deployed within the body lumen, such as the interior of a cardiac chamber. These types of positional sensors are typically used to determine the movement of a cardiac tissue surface or the electrical activity within the cardiac tissue. When a sufficient number of points have been sampled by the sensors, a “map” of the cardiac tissue may be generated.
Another conventional device utilizes an inflatable balloon which is typically introduced intravascularly in a deflated state and then inflated against the tissue region to be examined. Imaging is typically accomplished by an optical fiber or other apparatus such as electronic chips for viewing the tissue through the membrane(s) of the inflated balloon. Moreover, the balloon must generally be inflated for imaging. Other conventional balloons utilize a cavity or depression formed at a distal end of the inflated balloon. This cavity or depression is pressed against the tissue to be examined and is flushed with a clear fluid to provide a clear pathway through the blood.
However, such imaging balloons have many inherent disadvantages. For instance, such balloons generally require that the balloon be inflated to a relatively large size which may undesirably displace surrounding tissue and interfere with fine positioning of the imaging system against the tissue. Moreover, the working area created by such inflatable balloons are generally cramped and limited in size. Furthermore, inflated balloons may be susceptible to pressure changes in the surrounding fluid. For example, if the environment surrounding the inflated balloon undergoes pressure changes, e.g., during systolic and diastolic pressure cycles in a beating heart, the constant pressure change may affect the inflated balloon volume and its positioning to produce unsteady or undesirable conditions for optimal tissue imaging. Additionally, imaging balloons are subject to producing poor or blurred tissue images if the balloon is not firmly pressed against the tissue surface because of intervening blood between the balloon and tissue.
Accordingly, these types of imaging modalities are generally unable to provide desirable images useful for sufficient diagnosis and therapy of the endoluminal structure, due in part to factors such as dynamic forces generated by the natural movement of the heart. Moreover, anatomic structures within the body can occlude or obstruct the image acquisition process. Also, the presence and movement of opaque bodily fluids such as blood generally make in vivo imaging of tissue regions within the heart difficult. Moreover, once a visual image of a tissue region is acquired in vivo, there may be additional difficulties in assessing the condition of the underlying tissue for appropriate treatments or treatment parameters.
Thus, a tissue imaging system which is able to provide real-time in vivo images and assessments of tissue regions within body lumens such as the heart through opaque media such as blood and which also provide instruments for therapeutic procedures upon the visualized tissue are desirable.
In describing the tissue imaging and manipulation apparatus that may be utilized for procedures within a body lumen, such as the heart, in which visualization of the surrounding tissue is made difficult, if not impossible, by medium contained within the lumen such as blood, is described below. Generally, such a tissue imaging and manipulation apparatus comprises an optional delivery catheter or sheath through which a deployment catheter and imaging hood may be advanced for placement against or adjacent to the tissue to be imaged.
The deployment catheter may define a fluid delivery lumen therethrough as well as an imaging lumen within which an optical imaging fiber or assembly may be disposed for imaging tissue. When deployed, the imaging hood may be expanded into any number of shapes, e.g., cylindrical, conical as shown, semi-spherical, etc., provided that an open area or field is defined by the imaging hood. The open area is the area through which the tissue region of interest may be imaged. Additionally, the tissue may be viewed not only through the aperture but also through the distal membrane. The imaging hood may also define an atraumatic contact lip or edge for placement or abutment against the tissue region of interest. Moreover, the distal end of the deployment catheter or separate manipulatable catheters may be articulated through various controlling mechanisms such as push-pull wires manually or via computer control
The deployment catheter may also be stabilized relative to the tissue surface through various methods. For instance, inflatable stabilizing balloons positioned along a length of the catheter may be utilized, or tissue engagement anchors may be passed through or along the deployment catheter for temporary engagement of the underlying tissue.
In operation, after the imaging hood has been deployed, fluid may be pumped at a positive pressure through the fluid delivery lumen until the fluid fills the open area completely and displaces any blood from within the open area. The fluid may comprise any biocompatible fluid, e.g., saline, water, plasma, Fluorinert™, etc., which is sufficiently transparent to allow for relatively undistorted visualization through the fluid. The fluid may be pumped continuously or intermittently to allow for image capture by an optional processor which may be in communication with the assembly.
In an exemplary variation for imaging tissue surfaces within a heart chamber containing blood, the tissue imaging and treatment system may generally comprise a catheter body having a lumen defined therethrough, a visualization element disposed adjacent the catheter body, the visualization element having a field of view, a transparent or translucent fluid source in fluid communication with the lumen, and a barrier or membrane extendable from the catheter body to localize, between the visualization element and the field of view, displacement of blood by transparent fluid that flows from the lumen, and an instrument translatable through the displaced blood for performing any number of treatments upon the tissue surface within the field of view. The imaging hood may be formed into any number of configurations and the imaging assembly may also be utilized with any number of therapeutic tools which may be deployed through the deployment catheter.
More particularly in certain variations, the tissue visualization system may comprise components including the imaging hood, where the hood may further include a membrane having a main aperture and additional optional openings disposed over the distal end of the hood. An introducer sheath or the deployment catheter upon which the imaging hood is disposed may further comprise a steerable segment made of multiple adjacent links which are pivotably connected to one another and which may be articulated within a single plane or multiple planes. The deployment catheter itself may be comprised of a multiple lumen extrusion, such as a four-lumen catheter extrusion, which is reinforced with braided stainless steel fibers to provide structural support. The proximal end of the catheter may be coupled to a handle for manipulation and articulation of the system.
To provide visualization, an imaging element such as a fiberscope or electronic imager such as a solid state camera, e.g., CCD or CMOS, may be mounted, e.g., on a shape memory wire, and positioned within or along the hood interior. A fluid reservoir and/or pump (e.g., syringe, pressurized intravenous bag, etc.) may be fluidly coupled to the proximal end of the catheter to hold the translucent fluid such as saline or contrast medium as well as for providing the pressure to inject the fluid into the imaging hood.
In clearing the hood of blood and/or other bodily fluids, it is generally desirable to purge the hood in an efficient manner by minimizing the amount of clearing fluid, such as saline, introduced into the hood and thus into the body. As excessive saline delivered into the blood stream of patients with poor ventricular function may increase the risk of heart failure and pulmonary edema, minimizing or controlling the amount of saline discharged during various therapies, such as atrial fibrillation ablation, atrial flutter ablation, transseptal puncture, etc. may be generally desirable.
Steering of the hood assembly via controls on the handle may present some difficulties particularly when the catheter assembly has been contorted into various configurations by patient anatomies. This contortion may result in a mismatch between the steering controls and the corresponding movement on the screen of the in-vivo visualization system potentially leading to the user having to make constant micro movements on the steering controls to mentally re-map the direction of movement on the screen to the steering controls. This constant readjustment increases procedure times and may put undue stress and frustration on the user performing the treatment. This may continue to exist even with the addition of three-dimensional visualization systems as the movement of the catheter hood may not correspond to the real-time images viewed on the screen projecting the tissue images. Directional indicators on the visualization screen, in-vivo visualization screen, as well as on the steering controls may help to give the user a sense of orientation of the catheter device with respect to the in-vivo image being viewed. With this sense of orientation, users of the catheter device may be intuitively aware of the direction in which they should manipulate the tip of the device in order to access a specific region of anatomy.
In order to help physicians gain a better sense of the catheter hood orientation, color coded directional indicators, e.g., illustrated as dots or other symbols, may used to represent a specific section of the catheter hood. At least one of these color coded dots or symbols may be placed on a representation of the catheter assembly on the monitor, on the in vivo visualization monitor, and on the steering controls of the catheter handle. For illustrative purposes, the dots or symbols (which may also be optionally color-coded) may represent one of four directional indicators which may be represented on the monitors.
In yet another variation, one or more of the directional indicators located on the handle assembly may be configured as tactile sensors. When a user places their hand or finger upon one of the tactile sensors, the corresponding directional indicator displayed on the positional image may begin to blink, flash, or otherwise provide some indication that the corresponding direction on the control handle has been activated thus giving the user an immediate indication as to which portion of the handle control to manipulate without having to move their eyes from the monitors. The touch-sensitive sensors located on the handle assembly may be configured as touch-sensitive sensors utilizing any number of known mechanisms, such as capacitive sensors or pressure-sensitive sensors, etc.
Aside from the use of directional indicators and generated positional information, other mechanisms may be utilized for making the manipulation and steering of the hood relative to the body more intuitive. One example may utilize rotation of the image on the monitor showing the visualized tissue to affix a direction on the monitor to a direction of mechanical actuation on the control handle depending upon how the handle is re-orientated. In another variation, rather than rotating the images of the tissue based on the movement and rotation of the catheter handle, the images of the tissue may be fixed and the steering controls instead may be remapped.
In yet another variation for facilitating tissue treatment, the captured visual image of the tissue as imaged through the hood may be projected and mapped to the representative map of the tissue anatomy. Being able to visualize the “active spot” that is being visualized through the hood by mapping it onto the surface of the representative three-dimensional model may allow the physician to more accurately navigate the anatomy. When visualizing and treating tissue using the visualization system, the catheter hood may not necessarily be visualizing the tissue that is seen on the in vivo visualization system. This may occur due to a variety of reasons such as non-perpendicularity of the hood to the tissue surface or contortion of the hood. Because the active spot moves as the catheter hood is being moved, this may give the physician a greater awareness and confidence on both the visualization systems.
In yet another example, way-pointing methods may also be utilized to facilitate tissue treatment by the physician. Way-pointing is a pre-operative method that allows the physician to map out the ablation procedure by selecting lesion sites on the three-dimensional model of the anatomy. This data may be then transmitted to the catheter system which may generate and project approximated lesion boundaries to be formed as well as the navigational information to guide the hood from one lesion to another as the procedure progresses. Such a way-pointing system may prevent the user from becoming disoriented in the anatomy of the heart and may effectively speed procedure times while ensuring that lesions are contiguously formed, if necessary or desired, by showing lesion boundaries.
Additionally and/or alternatively, other methods for helping the user to maintain spatial awareness of the surrounding tissue and anatomical features may also be utilized for facilitating navigation, safety, procedure efficacy, etc. The features to be displayed may be pre-selected on the three-dimensional visualization model prior to treatment. These points of interest may allow the user to establish a base of reference when they are viewing the images of tissue on the monitor. Additionally, the indication of surrounding tissue regions may help to ensure the avoidance of inadvertently treating tissue surrounding the tissue region of interest.
Yet another example for facilitating tissue treatment procedures may utilize the augmentation of images utilizing previously captured images. For instance, captured images previously visualized through the hood and recorded may be compiled and stitched relative to one another to provide a seamless interior map of the anatomy. This image stitching may present an actual map of the interior of the heart instead of an approximate three-dimensional model. Moreover, the images can also be mapped such that they take on the contours of the model. Being able to see the actual visual inside the heart may increase physician confidence and also the speed of the procedure.
Procedure guidance systems are particularly useful when the user may be unfamiliar with the device and its capabilities or wish to facilitate the procedure by minimizing steering decisions from one ablation point to another. Such a system may function by first allowing the user to select potential ablation sites, e.g., in proximity to a pulmonary vein ostium, on either a pre-operative three-dimensional model or on a uniquely generated three-dimensional model. Physicians can then navigate the catheter hood into the particular orientation before performing ablation. Additionally, for steerable sections with a plurality of sensors, the steerable section can be graphically represented as well.
Reconfiguring a tissue visualization and treatment device from a low profile delivery configuration for intravascular delivery through the vessels of a patient to a deployed and expanded configuration may subject the distal end effector used for visualization and/or treatment, such as energy delivery, to potentially severe mechanical stresses (e.g., torsion, compression, tension, shearing, etc.). For example, a reconfigurable hood which undergoes a shape change from its collapsed configuration to an expanded conical shape may utilize a distensible, collapsible, and/or reconfigurable substrate which may utilize electrode placement and electrical connection assemblies which are robust and able to withstand such stresses. Such electrical connection assemblies may be shielded or insulated from contacting other structures so as to present a smooth or unobstructive profile for reconfiguring with the hood.
Turning now to the tissue-imaging and manipulation apparatus, such an apparatus may have one or more electrodes positioned thereon and also provide real-time images in vivo of tissue regions within a body lumen such as a heart, which is filled with blood flowing dynamically therethrough. The apparatus is also able to provide intravascular tools and instruments for performing various procedures upon the imaged tissue regions. Such an apparatus may be utilized for many procedures, e.g., facilitating transseptal access to the left atrium, cannulating the coronary sinus, diagnosis of valve regurgitation/stenosis, valvuloplasty, atrial appendage closure, arrhythmogenic focus ablation, among other procedures.
One variation of a tissue access and imaging apparatus is shown in the detail perspective views of
When the imaging and manipulation assembly 10 is ready to be utilized for imaging tissue, imaging hood 12 may be advanced relative to catheter 14 and deployed from a distal opening of catheter 14, as shown by the arrow. Upon deployment, imaging hood 12 may be unconstrained to expand or open into a deployed imaging configuration, as shown in
Imaging hood 12 may be attached at interface 24 to a deployment catheter 16 which may be translated independently of deployment catheter or sheath 14. Attachment of interface 24 may be accomplished through any number of conventional methods. Deployment catheter 16 may define a fluid delivery lumen 18 as well as an imaging lumen 20 within which an optical imaging fiber or assembly may be disposed for imaging tissue. When deployed, imaging hood 12 may expand into any number of shapes, e.g., cylindrical, conical as shown, semi-spherical, etc., provided that an open area or field 26 is defined by imaging hood 12. The open area 26 is the area within which the tissue region of interest may be imaged. Imaging hood 12 may also define an atraumatic contact lip or edge 22 for placement or abutment against the tissue region of interest. Moreover, the diameter of imaging hood 12 at its maximum fully deployed diameter, e.g., at contact lip or edge 22, is typically greater relative to a diameter of the deployment catheter 16 (although a diameter of contact lip or edge 22 may be made to have a smaller or equal diameter of deployment catheter 16). For instance, the contact edge diameter may range anywhere from 1 to 5 times (or even greater, as practicable) a diameter of deployment catheter 16.
As seen in the example of
Although contact edge 22 need not directly contact the underlying tissue, it is at least preferably brought into close proximity to the tissue such that the flow of clear fluid 28 from open area 26 may be maintained to inhibit significant backflow of blood 30 back into open area 26. Contact edge 22 may also be made of a soft elastomeric material such as certain soft grades of silicone or polyurethane, as typically known, to help contact edge 22 conform to an uneven or rough underlying anatomical tissue surface. Once the blood 30 has been displaced from imaging hood 12, an image may then be viewed of the underlying tissue through the clear fluid 30. This image may then be recorded or available for real-time viewing for performing a therapeutic procedure. The positive flow of fluid 28 may be maintained continuously to provide for clear viewing of the underlying tissue. Alternatively, the fluid 28 may be pumped temporarily or sporadically only until a clear view of the tissue is available to be imaged and recorded, at which point the fluid flow 28 may cease and blood 30 may be allowed to seep or flow back into imaging hood 12. This process may be repeated a number of times at the same tissue region or at multiple tissue regions.
In utilizing the imaging hood 12 in any one of the procedures described herein, the hood 12 may have an open field which is uncovered and clear to provide direct tissue contact between the hood interior and the underlying tissue to effect any number of treatments upon the tissue, as described above. Yet in additional variations, imaging hood 12 may utilize other configurations. An additional variation of the imaging hood 12 is shown in the perspective and end views, respectively, of
Aperture 42 may function generally as a restricting passageway to reduce the rate of fluid out-flow from the hood 12 when the interior of the hood 12 is infused with the clear fluid through which underlying tissue regions may be visualized. Aside from restricting out-flow of clear fluid from within hood 12, aperture 42 may also restrict external surrounding fluids from entering hood 12 too rapidly. The reduction in the rate of fluid out-flow from the hood and blood in-flow into the hood may improve visualization conditions as hood 12 may be more readily filled with transparent fluid rather than being filled by opaque blood which may obstruct direct visualization by the visualization instruments.
Moreover, aperture 42 may be aligned with catheter 16 such that any instruments (e.g., piercing instruments, guidewires, tissue engagers, etc.) that are advanced into the hood interior may directly access the underlying tissue uninhibited or unrestricted for treatment through aperture 42. In other variations wherein aperture 42 may not be aligned with catheter 16, instruments passed through catheter 16 may still access the underlying tissue by simply piercing through membrane 40.
In an additional variation,
Additional details of tissue imaging and manipulation systems and methods which may be utilized with apparatus and methods described herein are further described, for example, in U.S. patent application Ser. No. 11/259,498 filed Oct. 25, 2005 (U.S. Pat. Pub. 2006/0184048 A1), which is incorporated herein by reference in its entirety.
In utilizing the devices and methods above, various procedures may be accomplished. One example of such a procedure is crossing a tissue region such as in a transseptal procedure where a septal wall is pierced and traversed, e.g., crossing from a right atrial chamber to a left atrial chamber in a heart of a subject. Generally, in piercing and traversing a septal wall, the visualization and treatment devices described herein may be utilized for visualizing the tissue region to be pierced as well as monitoring the piercing and access through the tissue. Details of transseptal visualization catheters and methods for transseptal access which may be utilized with the apparatus and methods described herein are described in U.S. patent application Ser. No. 11/763,399 filed Jun. 14, 2007 (U.S. Pat. Pub. 2007/0293724 A1), which is incorporated herein by reference in its entirety. Additionally, details of tissue visualization and manipulation catheter which may be utilized with apparatus and methods described herein are described in U.S. patent application Ser. No. 11/259,498 filed Oct. 25, 2005 (U.S. Pat. Pub. 2006/0184048 A1), which is incorporated herein by reference in its entirety.
In clearing the hood of blood and/or other bodily fluids, it is generally desirable to purge the hood in an efficient manner by minimizing the amount of clearing fluid, such as saline, introduced into the hood and thus into the body. As excessive saline delivered into the blood stream of patients with poor ventricular function may increase the risk of heart failure and pulmonary edema, minimizing or controlling the amount of saline discharged during various therapies, such as atrial fibrillation ablation, atrial flutter ablation, transseptal puncture, etc. may be generally desirable.
Turning now to the electrode assemblies and connection systems utilized with the collapsible hood, various examples are described herein which illustrate variations for electrode positioning along the hood which may minimize or reduce the degree of stress imparted to the electrode assemblies. These electrodes (e.g., electrode pairs) may be used to deliver electrical energy such as radio-frequency energy to tissue in direct contact with or in proximity to the electrodes to form lesions upon the tissue surface as well as underlying tissue regions. Additionally, the electrodes or electrode pairs may be positioned about the hood in a uniform or non-uniform manner depending upon the desired configuration. Moreover, these electrodes may also be used to deliver energy into and/or through the purging fluid which may contact the electrodes for conducting the energy through the fluid and into the underlying tissue region being treated. Alternatively, one or more of these electrodes may also be used to detect and/or measure any electrophysiological activity of the contacted tissue prior to, during, or after tissue treatment.
While specific examples of the visualization and treatment hood are shown herein, other variations and examples of hoods and tissue treatment systems may be utilized with the devices and methods described herein. For example, the hoods, systems, and other features as described in Ser. No. 11/259,498 filed Oct. 25, 2005 (U.S. Pat. Pub. 2006/0184048 A1); Ser. No. 11/775,837 filed Jul. 10, 2007 (U.S. Pat. Pub. 2008/0009747 A1); Ser. No. 11/828,267 filed Jul. 25, 2007 (U.S. Pat. Pub. No. 2008/0033290 A1); Ser. No. 12/118,439 filed May 9, 2008 (U.S. Pat. Pub. 2009/0030412 A1); Ser. No. 12/201,811 filed Aug. 29, 2008 (U.S. Pat. Pub. 2009/0062790 A1); and Ser. No. 12/209,057 filed Sep. 11, 2008 (U.S. Pat. Pub. 20090076498 A1), may be utilized herewith. Each of these applications is incorporated herein by reference in its entirety.
In particular, such assemblies, apparatus, and methods may be utilized for treatment of various conditions, e.g., arrhythmias, through ablation under direct visualization. Details of examples for the treatment of arrhythmias under direct visualization which may be utilized with apparatus and methods described herein are described, for example, in U.S. patent application Ser. No. 11/775,819 filed Jul. 10, 2007 (U.S. Pat. Pub. No. 2008/0015569 A1), which is incorporated herein by reference in its entirety. Variations of the tissue imaging and manipulation apparatus may be configured to facilitate the application of bipolar energy delivery, such as radio-frequency (RF) ablation, to an underlying target tissue for treatment in a controlled manner while directly visualizing the tissue during the bipolar ablation process as well as confirming (visually and otherwise) appropriate treatment thereafter.
Steering of the hood assembly via controls on the handle may present some difficulties particularly when the catheter assembly has been contorted into various configurations by patient anatomies. This contortion may result in a mismatch between the steering controls and the corresponding movement on the screen of the in-vivo visualization system potentially leading to the user having to make constant micro movements on the steering controls to mentally re-map the direction of movement on the screen to the steering controls. This constant readjustment increases procedure times and may put undue stress and frustration on the user performing the treatment. This may continue to exist even with the addition of three-dimensional visualization systems as the movement of the catheter hood 12 may not correspond to the real-time images viewed on the screen projecting the tissue images. Directional indicators on the visualization screen, in-vivo visualization screen, as well as on the steering controls may help to give the user a sense of orientation of the catheter device with respect to the in-vivo image being viewed. With this sense of orientation, users of the catheter device may be intuitively aware of the direction in which they should manipulate the tip of the device in order to access a specific region of anatomy. Further details for use of directional indicators which may be utilized herein are shown and described in U.S. patent application Ser. No. 12/118,439 filed May 9, 2008 (U.S. Pat. Pub. No. 2009/0030412 A1), which is incorporated herein by reference in its entirety.
Turning now to the assembly view of
Additional control and navigation systems which may be utilized herein are shown and described in further detail in U.S. patent application Ser. No. 11/848,429 filed Aug. 31, 2007 (U.S. Pat. Pub. 2008/0097476 A1) and in Ser. No. 11/848,532 also filed Aug. 31, 2007 (U.S. Pat. Pub. 2009/0054803 A1), each of which is incorporated herein by reference in its entirety.
An intervening link 56 may couple the sections 52, 54 to one another and provide a terminal link to which one or more pull wires may be attached in controlling one or both sections. The distal steerable section 52 may utilize individual links 66 which allow for the section 52 to be articulated in a variety of different directions and angles, e.g., four-way steering, to enable omni-direction articulation. The individual links 66 may accordingly utilize a body member 68 having a pair of yoke members 70 positioned opposite to one another and extending distally from the body member 68 and each defining an opening. A pair of pins 72 may each extend radially in opposing directions from body member 68 and in a perpendicular plane relative to a plane defined by the yoke members 70. The pins 72 of each link 66 may be pivotably received by the yoke members 70 of an adjacent link 66 such that the pins 72 and yoke members 70 are joined in an alternating manner. This alternating connection allows for the serially aligned links 66 to be articulated omni-directionally.
The links 58 of the proximal steering section 54 may also comprise a pair of yoke members 62 positioned opposite to one another and extending distally from body member 60. However, the pins 64 may extend radially in opposing directions while remaining in the same plane as that defined by yoke members 62. When joined together in series, each pin 64 of each link 58 may be pivotably received by the yoke members 62 of an adjacent link 58. Yet when joined, the composite proximal steering section 54 may be constrained to bend planarly within a single plane relative to the rest of the deployment catheter.
The combined distal steerable section 52 and a proximal steerable section 54 results in a proximal steering section which can be articulated in a single plane to retroflex the entire distal assembly and a distal steering section which can then be articulated any number of directions, e.g., four-way steering, to access anatomical structures within the heart or any other lumen. The assembly may thus be used, e.g., to create circumferential lesions around the ostia of the pulmonary veins in the left atrium while the underlying tissue remains under direct visualization through the hood.
In order to help physicians gain a better sense of the catheter hood orientation, color coded directional indicators, e.g., illustrated as dots or other symbols, may used to represent a specific section of the catheter hood 12. At least one of these color coded dots or symbols may be placed on a representation of the catheter assembly on the monitor, on the in vivo visualization monitor, and on the steering controls of the catheter handle. For illustrative purposes, the dots or symbols (which may also be optionally color-coded) may represent one of four directional indicators which may be represented on the monitors, as shown in
The image of the positional information 100 may be seen where, e.g., a first directional indicator 102 shown as a blue dot, may be assigned a first position along the hood 12, a second directional indicator 104 shown as a red triangle, may be assigned a second position along the hood 12, a third directional indicator 106 shown as a yellow star may be assigned a third position along the hood 12, and a fourth directional indicator 108 shown as a green dot may be positioned along a fourth position along the hood 12. The dots or symbols are shown for illustrative purposes and they may represented by any number of symbols, letters, numbers, etc. so long as they represent indicators which are distinct from one another. Moreover, color-coding may be optionally incorporated and the number and positioning of the indicators may be varied so long as different directions may be discerned by the placement and number of indicators.
In addition to the generated representative orientation information shown in the displayed image 100, the captured images of the tissue which are visualized through the hood 12 and displayed, e.g., on a second monitor, may be seen in the visualized tissue image 94 of
As previously mentioned and as seen in the perspective view of
As the user visualizes the tissue through hood 12, if the hood 12 needed to be repositioned in any particular direction along the tissue, the user may note the direction to be moved relative to the indicators marked on hood 12 and may thus manipulate the controls on control 86 accordingly such that movement of the controls in the chosen direction may articulate the hood 12 in the same direction. Additionally, the generated image of the hood orientation may also display the directional indicators corresponding to the indicators on the hood 12 and the handle 80. Such a feature may be highly advantageous relative to the absence of visual markings as it may be difficult for the user to steer the hood 12 in a desired direction after it is inserted into the patient's body due to the changes in hood orientation relative to the handle 80 orientation.
In yet another variation, one or more of the directional indicators located on the handle assembly 80 may be configured as tactile sensors. An example is shown in the perspective view of
Aside from the use of directional indicators and generated positional information, other mechanisms may be utilized for making the manipulation and steering of the hood relative to the body more intuitive. One example may utilize rotation of the image on the monitor showing the visualized tissue to affix a direction on the monitor to a direction of mechanical actuation on the control handle depending upon how the handle is re-orientated. For example, as shown in the perspective view of
Because of the tortuous nature of patient anatomies, the handle assembly 80 may be rotated about its longitudinal axis relative to the user to position the hood at the distal end of the catheter assembly within the body. As shown in the perspective view of
Such movement may be achieved by mechanical mechanisms, such as having a portion of the catheter handle 80 being rotatable about its longitudinal axis to maintain a consistent position of the handle relative to the user. Examples of such a catheter handle assembly as shown and described in further detail in U.S. Prov. App. 61/286,283 filed Dec. 14, 2009 and 61/297,462 filed Jan. 22, 2010, each of which is incorporated herein by reference in its entirety. Alternatively, one or more accelerometers or positional sensors may be incorporated into the handle assembly 80 which communicate with a processor such that movement of the handle assembly 80 from an initial calibrated position may automatically rotate the images on the monitor to align in a corresponding manner with the rotation of the handle assembly 80.
In another variation, rather than rotating the images of the tissue based on the movement and rotation of the catheter handle, the images of the tissue may be fixed and the steering controls instead may be remapped. An example is shown in the perspective view of
In generating a representative image of the hood assembly orientation relative to the tissue surface, one or more sensors may be positioned along the catheter device for generating the images, as previously described, e.g., in U.S. patent application Ser. No. 11/848,532 filed Aug. 31, 2007 (U.S. Pat. Pub. 2009/0054803 A1), which has been previously incorporated herein by reference above. Additional sensors may be placed along the steerable sections of the catheter assembly such that an image of the relative positioning of the catheter and hood assembly may be generated for graphical representation. As shown in the perspective view of
In yet another variation for facilitating tissue treatment, the captured visual image of the tissue as imaged through the hood 12 may be projected and mapped to the representative map of the tissue anatomy. Being able to visualize the “active spot” 140 that is being visualized through the hood, shown by its representation 132, by mapping it onto the surface of the representative three-dimensional model 130 may allow the physician to more accurately navigate the anatomy, as shown in
The three-dimensional model 130 may be normally created by a sensor probe which is pushed against the walls of the anatomy. The associated data points are taken and a representative model is built. Often the model is inaccurate and physicians rely on approximations to make decisions on locations for tissue treatment. Cross-referencing the data points of the three-dimensional model with images viewed by the in vivo visualization system can be helpful in making adjustments and adding further detail to the model. Visual features such as pulmonary vein ostia could potentially be referenced to the three-dimensional model by location and contour matching software algorithms in addition to manual point selection.
In yet another example, way-pointing methods may also be utilized to facilitate tissue treatment by the physician. Way-pointing is a pre-operative method that allows the physician to map out the ablation procedure by selecting lesion sites on the three-dimensional model of the anatomy. As shown in the image model 130 of
Additionally and/or alternatively, other methods for helping the user to maintain spatial awareness of the surrounding tissue and anatomical features may also be utilized for facilitating navigation, safety, procedure efficacy, etc.
Yet another example for facilitating tissue treatment procedures may utilize the augmentation of images utilizing previously captured images. For instance, as shown in the three-dimensional model 180 of
Procedure guidance systems are particularly useful when the user may be unfamiliar with the device and its capabilities or wish to facilitate the procedure by minimizing steering decisions from one ablation point to another. Such a system may function by first allowing the user to select potential ablation sites 192, e.g., in proximity to a pulmonary vein PV ostium, on either a pre-operative three-dimensional model or on a uniquely generated three-dimensional model 190 as shown in
The applications of the disclosed invention discussed above are not limited to certain treatments or regions of the body, but may include any number of other treatments and areas of the body. Modification of the above-described methods and devices for carrying out the invention, and variations of aspects of the invention that are obvious to those of skill in the arts are intended to be within the scope of this disclosure. Moreover, various combinations of aspects between examples are also contemplated and are considered to be within the scope of this disclosure as well.
This application claims the benefit of priority to U.S. Prov. App. 61/177,618 filed May 12, 2009, which is incorporated herein by reference in its entirety. This is also a continuation-in-part of U.S. patent application Ser. No. 11/763,399 filed Jun. 14, 2007, which claims the benefit of priority to the following U.S. Prov. App. Ser. Nos. 60/804,801 filed Jun. 14, 2006; 60/806,924 filed Jul. 10, 2006; 60/806,926 filed Jul. 10, 2006; 60/871,415 filed Dec. 21, 2006; 60/871,424 filed Dec. 21, 2006; 60/888,242 filed Feb. 5, 2007.
Number | Name | Date | Kind |
---|---|---|---|
623022 | Johnson | Apr 1899 | A |
2305462 | Wolf | Dec 1942 | A |
2453862 | Peter | Nov 1948 | A |
3559651 | Moss | Feb 1971 | A |
3874388 | King et al. | Apr 1975 | A |
3903877 | Terada | Sep 1975 | A |
4175545 | Termanini | Nov 1979 | A |
4326529 | Doss et al. | Apr 1982 | A |
4445892 | Hussein et al. | May 1984 | A |
4470407 | Hussein et al. | Sep 1984 | A |
4517976 | Murakoshi et al. | May 1985 | A |
4569335 | Tsuno | Feb 1986 | A |
4576146 | Kawazoe et al. | Mar 1986 | A |
4615333 | Taguchi | Oct 1986 | A |
4619247 | Inoue et al. | Oct 1986 | A |
4676258 | Inokuchi et al. | Jun 1987 | A |
4681093 | Ono et al. | Jul 1987 | A |
4709698 | Johnston et al. | Dec 1987 | A |
4710192 | Liotta et al. | Dec 1987 | A |
4727418 | Kato et al. | Feb 1988 | A |
4784133 | Mackin | Nov 1988 | A |
4838246 | Hahn et al. | Jun 1989 | A |
4848323 | Marijnissen et al. | Jul 1989 | A |
4911148 | Sosnowski et al. | Mar 1990 | A |
4914521 | Adair | Apr 1990 | A |
4943290 | Rexroth et al. | Jul 1990 | A |
4950285 | Wilk | Aug 1990 | A |
4957484 | Murtfeldt | Sep 1990 | A |
4961738 | Mackin | Oct 1990 | A |
4976710 | Mackin | Dec 1990 | A |
4991578 | Cohen | Feb 1991 | A |
4994069 | Ritchart et al. | Feb 1991 | A |
4998916 | Hammerslag et al. | Mar 1991 | A |
4998972 | Chin et al. | Mar 1991 | A |
5047028 | Qian | Sep 1991 | A |
5057106 | Kasevich et al. | Oct 1991 | A |
5090959 | Samson et al. | Feb 1992 | A |
5123428 | Schwarz | Jun 1992 | A |
RE34002 | Adair | Jul 1992 | E |
5156141 | Krebs et al. | Oct 1992 | A |
5171259 | Inoue | Dec 1992 | A |
5281238 | Chin et al. | Jan 1994 | A |
5282827 | Kensey et al. | Feb 1994 | A |
5306234 | Johnson | Apr 1994 | A |
5313943 | Houser et al. | May 1994 | A |
5330496 | Alferness | Jul 1994 | A |
5334159 | Turkel | Aug 1994 | A |
5334193 | Nardella | Aug 1994 | A |
5336252 | Cohen | Aug 1994 | A |
5339800 | Wiita et al. | Aug 1994 | A |
5348554 | Imran et al. | Sep 1994 | A |
5353792 | Lubbers et al. | Oct 1994 | A |
5370647 | Graber et al. | Dec 1994 | A |
5373840 | Knighton | Dec 1994 | A |
5375612 | Cottenceau et al. | Dec 1994 | A |
5385148 | Lesh et al. | Jan 1995 | A |
5391182 | Chin | Feb 1995 | A |
5403326 | Harrison et al. | Apr 1995 | A |
5405376 | Mulier et al. | Apr 1995 | A |
5421338 | Crowley et al. | Jun 1995 | A |
5431649 | Mulier et al. | Jul 1995 | A |
5453785 | Lenhardt et al. | Sep 1995 | A |
5462521 | Brucker et al. | Oct 1995 | A |
5471515 | Fossum et al. | Nov 1995 | A |
5498230 | Adair | Mar 1996 | A |
5505730 | Edwards | Apr 1996 | A |
5515853 | Smith et al. | May 1996 | A |
5527338 | Purdy | Jun 1996 | A |
5549603 | Feiring | Aug 1996 | A |
5558619 | Kami et al. | Sep 1996 | A |
5571088 | Lennox et al. | Nov 1996 | A |
5575756 | Karasawa et al. | Nov 1996 | A |
5575810 | Swanson et al. | Nov 1996 | A |
5584872 | LaFontaine et al. | Dec 1996 | A |
5591119 | Adair | Jan 1997 | A |
5593422 | Muijs Van de Moer et al. | Jan 1997 | A |
5593424 | Northrup, III | Jan 1997 | A |
5672153 | Lax et al. | Sep 1997 | A |
5676693 | LaFontaine | Oct 1997 | A |
5681308 | Edwards et al. | Oct 1997 | A |
5695448 | Kimura et al. | Dec 1997 | A |
5697281 | Eggers et al. | Dec 1997 | A |
5697882 | Eggers et al. | Dec 1997 | A |
5709224 | Behl et al. | Jan 1998 | A |
5713907 | Hogendijk et al. | Feb 1998 | A |
5713946 | Ben-Haim | Feb 1998 | A |
5716321 | Kerin et al. | Feb 1998 | A |
5722403 | McGee et al. | Mar 1998 | A |
5725523 | Mueller | Mar 1998 | A |
5746747 | McKeating | May 1998 | A |
5749846 | Edwards et al. | May 1998 | A |
5749890 | Shaknovich | May 1998 | A |
5754313 | Pelchy et al. | May 1998 | A |
5766137 | Omata | Jun 1998 | A |
5769846 | Edwards et al. | Jun 1998 | A |
5792045 | Adair | Aug 1998 | A |
5797903 | Swanson et al. | Aug 1998 | A |
5823947 | Yoon et al. | Oct 1998 | A |
5827268 | Laufer | Oct 1998 | A |
5829447 | Stevens et al. | Nov 1998 | A |
5842973 | Bullard | Dec 1998 | A |
5843118 | Sepetka et al. | Dec 1998 | A |
5848969 | Panescu et al. | Dec 1998 | A |
5860974 | Abele | Jan 1999 | A |
5860991 | Klein et al. | Jan 1999 | A |
5865791 | Whayne et al. | Feb 1999 | A |
5873815 | Kerin et al. | Feb 1999 | A |
5879366 | Shaw et al. | Mar 1999 | A |
5895417 | Pomeranz et al. | Apr 1999 | A |
5897487 | Ouchi | Apr 1999 | A |
5897553 | Mulier et al. | Apr 1999 | A |
5902328 | LaFontaine et al. | May 1999 | A |
5904651 | Swanson et al. | May 1999 | A |
5908445 | Whayne et al. | Jun 1999 | A |
5925038 | Panescu et al. | Jul 1999 | A |
5928250 | Koike et al. | Jul 1999 | A |
5929901 | Adair et al. | Jul 1999 | A |
5941845 | Tu et al. | Aug 1999 | A |
5944690 | Falwell et al. | Aug 1999 | A |
5964755 | Edwards | Oct 1999 | A |
5968053 | Revelas | Oct 1999 | A |
5971983 | Lesh | Oct 1999 | A |
5986693 | Adair et al. | Nov 1999 | A |
5997571 | Farr et al. | Dec 1999 | A |
6004269 | Crowley et al. | Dec 1999 | A |
6012457 | Lesh | Jan 2000 | A |
6024740 | Lesh et al. | Feb 2000 | A |
6027501 | Goble et al. | Feb 2000 | A |
6036685 | Mueller | Mar 2000 | A |
6043839 | Adair et al. | Mar 2000 | A |
6047218 | Whayne et al. | Apr 2000 | A |
6063077 | Schaer | May 2000 | A |
6063081 | Mulier et al. | May 2000 | A |
6068653 | LaFontaine | May 2000 | A |
6071279 | Whayne et al. | Jun 2000 | A |
6071302 | Sinofsky et al. | Jun 2000 | A |
6081740 | Gombrich et al. | Jun 2000 | A |
6086528 | Adair | Jul 2000 | A |
6086534 | Kesten | Jul 2000 | A |
6099498 | Addis | Aug 2000 | A |
6099514 | Sharkey et al. | Aug 2000 | A |
6102905 | Baxter et al. | Aug 2000 | A |
6112123 | Kelleher et al. | Aug 2000 | A |
6115626 | Whayne et al. | Sep 2000 | A |
6123703 | Tu et al. | Sep 2000 | A |
6123718 | Tu et al. | Sep 2000 | A |
6129724 | Fleischman et al. | Oct 2000 | A |
6139508 | Simpson et al. | Oct 2000 | A |
6142993 | Whayne et al. | Nov 2000 | A |
6152144 | Lesh et al. | Nov 2000 | A |
6156350 | Constantz | Dec 2000 | A |
6159203 | Sinofsky | Dec 2000 | A |
6161543 | Cox et al. | Dec 2000 | A |
6164283 | Lesh | Dec 2000 | A |
6167297 | Benaron | Dec 2000 | A |
6168591 | Sinofsky | Jan 2001 | B1 |
6168594 | LaFontaine et al. | Jan 2001 | B1 |
6174307 | Daniel et al. | Jan 2001 | B1 |
6178346 | Amundson et al. | Jan 2001 | B1 |
6190381 | Olsen et al. | Feb 2001 | B1 |
6211904 | Adair et al. | Apr 2001 | B1 |
6224553 | Nevo | May 2001 | B1 |
6231561 | Frazier et al. | May 2001 | B1 |
6234995 | Peacock, III | May 2001 | B1 |
6235044 | Root et al. | May 2001 | B1 |
6237605 | Vaska et al. | May 2001 | B1 |
6238393 | Mulier et al. | May 2001 | B1 |
6240312 | Alfano et al. | May 2001 | B1 |
6254598 | Edwards et al. | Jul 2001 | B1 |
6258083 | Daniel et al. | Jul 2001 | B1 |
6263224 | West | Jul 2001 | B1 |
6270492 | Sinofsky | Aug 2001 | B1 |
6275255 | Adair et al. | Aug 2001 | B1 |
6290689 | Delaney et al. | Sep 2001 | B1 |
6306081 | Ishikawa et al. | Oct 2001 | B1 |
6310642 | Adair et al. | Oct 2001 | B1 |
6311692 | Vaska et al. | Nov 2001 | B1 |
6314962 | Vaska et al. | Nov 2001 | B1 |
6314963 | Vaska et al. | Nov 2001 | B1 |
6315777 | Comben | Nov 2001 | B1 |
6315778 | Gambale et al. | Nov 2001 | B1 |
6322536 | Rosengart et al. | Nov 2001 | B1 |
6325797 | Stewart et al. | Dec 2001 | B1 |
6328727 | Frazier et al. | Dec 2001 | B1 |
6358247 | Altman et al. | Mar 2002 | B1 |
6358248 | Mulier et al. | Mar 2002 | B1 |
6375654 | McIntyre | Apr 2002 | B1 |
6379345 | Constantz | Apr 2002 | B1 |
6385476 | Osadchy et al. | May 2002 | B1 |
6387043 | Yoon | May 2002 | B1 |
6387071 | Constantz | May 2002 | B1 |
6394096 | Constantz | May 2002 | B1 |
6396873 | Goldstein et al. | May 2002 | B1 |
6398780 | Farley et al. | Jun 2002 | B1 |
6401719 | Farley et al. | Jun 2002 | B1 |
6409722 | Hoey et al. | Jun 2002 | B1 |
6416511 | Lesh et al. | Jul 2002 | B1 |
6419669 | Frazier et al. | Jul 2002 | B1 |
6423051 | Kaplan et al. | Jul 2002 | B1 |
6423055 | Farr et al. | Jul 2002 | B1 |
6423058 | Edwards et al. | Jul 2002 | B1 |
6428536 | Panescu et al. | Aug 2002 | B2 |
6436118 | Kayan | Aug 2002 | B1 |
6440061 | Wenner et al. | Aug 2002 | B1 |
6440119 | Nakada et al. | Aug 2002 | B1 |
6458151 | Saltiel | Oct 2002 | B1 |
6461327 | Addis et al. | Oct 2002 | B1 |
6464697 | Edwards et al. | Oct 2002 | B1 |
6474340 | Vaska et al. | Nov 2002 | B1 |
6475223 | Werp et al. | Nov 2002 | B1 |
6478769 | Parker | Nov 2002 | B1 |
6482162 | Moore | Nov 2002 | B1 |
6484727 | Vaska et al. | Nov 2002 | B1 |
6485489 | Teirstein et al. | Nov 2002 | B2 |
6488671 | Constantz et al. | Dec 2002 | B1 |
6494902 | Hoey et al. | Dec 2002 | B2 |
6497705 | Comben | Dec 2002 | B2 |
6500174 | Maguire et al. | Dec 2002 | B1 |
6502576 | Lesh | Jan 2003 | B1 |
6514249 | Maguire et al. | Feb 2003 | B1 |
6517533 | Swaminathan | Feb 2003 | B1 |
6527979 | Constantz et al. | Mar 2003 | B2 |
6532380 | Close et al. | Mar 2003 | B1 |
6533767 | Johansson et al. | Mar 2003 | B2 |
6537272 | Christopherson et al. | Mar 2003 | B2 |
6540733 | Constantz et al. | Apr 2003 | B2 |
6540744 | Hassett et al. | Apr 2003 | B2 |
6544195 | Wilson et al. | Apr 2003 | B2 |
6547780 | Sinofsky | Apr 2003 | B1 |
6558375 | Sinofsky et al. | May 2003 | B1 |
6558382 | Jahns et al. | May 2003 | B2 |
6562020 | Constantz et al. | May 2003 | B1 |
6572609 | Farr et al. | Jun 2003 | B1 |
6579285 | Sinofsky | Jun 2003 | B2 |
6585732 | Mulier et al. | Jul 2003 | B2 |
6587709 | Solf et al. | Jul 2003 | B2 |
6593884 | Gilboa et al. | Jul 2003 | B1 |
6605055 | Sinofsky et al. | Aug 2003 | B1 |
6613062 | Leckrone et al. | Sep 2003 | B1 |
6622732 | Constantz | Sep 2003 | B2 |
6626855 | Weng et al. | Sep 2003 | B1 |
6626899 | Houser et al. | Sep 2003 | B2 |
6626900 | Sinofsky et al. | Sep 2003 | B1 |
6635070 | Leeflang et al. | Oct 2003 | B2 |
6645202 | Pless et al. | Nov 2003 | B1 |
6650923 | Lesh et al. | Nov 2003 | B1 |
6658279 | Swanson et al. | Dec 2003 | B2 |
6659940 | Adler | Dec 2003 | B2 |
6673090 | Root et al. | Jan 2004 | B2 |
6676656 | Sinofsky | Jan 2004 | B2 |
6679836 | Couvillon, Jr. | Jan 2004 | B2 |
6682526 | Jones et al. | Jan 2004 | B1 |
6689128 | Sliwa, Jr. et al. | Feb 2004 | B2 |
6692430 | Adler | Feb 2004 | B2 |
6701581 | Senovich et al. | Mar 2004 | B2 |
6701931 | Sliwa, Jr. et al. | Mar 2004 | B2 |
6702780 | Gilboa et al. | Mar 2004 | B1 |
6704043 | Goldstein et al. | Mar 2004 | B2 |
6706039 | Mulier et al. | Mar 2004 | B2 |
6712798 | Constantz | Mar 2004 | B2 |
6719747 | Constantz et al. | Apr 2004 | B2 |
6719755 | Sliwa, Jr. et al. | Apr 2004 | B2 |
6730063 | Delaney et al. | May 2004 | B2 |
6736810 | Hoey et al. | May 2004 | B2 |
6751492 | Ben-Haim | Jun 2004 | B2 |
6755790 | Stewart et al. | Jun 2004 | B2 |
6755811 | Constantz | Jun 2004 | B1 |
6764487 | Mulier et al. | Jul 2004 | B2 |
6771996 | Bowe et al. | Aug 2004 | B2 |
6773402 | Govari et al. | Aug 2004 | B2 |
6780151 | Grabover et al. | Aug 2004 | B2 |
6805128 | Pless et al. | Oct 2004 | B1 |
6805129 | Pless et al. | Oct 2004 | B1 |
6811562 | Pless | Nov 2004 | B1 |
6833814 | Gilboa et al. | Dec 2004 | B2 |
6840923 | Lapcevic | Jan 2005 | B1 |
6840936 | Sliwa, Jr. et al. | Jan 2005 | B2 |
6849073 | Hoey et al. | Feb 2005 | B2 |
6858005 | Ohline et al. | Feb 2005 | B2 |
6858026 | Sliwa, Jr. et al. | Feb 2005 | B2 |
6863668 | Gillespie et al. | Mar 2005 | B2 |
6866651 | Constantz | Mar 2005 | B2 |
6887237 | McGaffigan | May 2005 | B2 |
6892091 | Ben-Haim et al. | May 2005 | B1 |
6896690 | Lambrecht et al. | May 2005 | B1 |
6899672 | Chin et al. | May 2005 | B2 |
6915154 | Docherty et al. | Jul 2005 | B1 |
6916284 | Moriyama | Jul 2005 | B2 |
6923805 | LaFontaine et al. | Aug 2005 | B1 |
6929010 | Vaska et al. | Aug 2005 | B2 |
6932809 | Sinofsky | Aug 2005 | B2 |
6939348 | Malecki et al. | Sep 2005 | B2 |
6942657 | Sinofsky et al. | Sep 2005 | B2 |
6949095 | Vaska et al. | Sep 2005 | B2 |
6953457 | Farr et al. | Oct 2005 | B2 |
6955173 | Lesh | Oct 2005 | B2 |
6962589 | Mulier et al. | Nov 2005 | B2 |
6971394 | Sliwa, Jr. et al. | Dec 2005 | B2 |
6974464 | Quijano et al. | Dec 2005 | B2 |
6979290 | Mourlas et al. | Dec 2005 | B2 |
6982740 | Adair et al. | Jan 2006 | B2 |
6984232 | Vanney et al. | Jan 2006 | B2 |
6994094 | Schwartz | Feb 2006 | B2 |
7019610 | Creighton, IV et al. | Mar 2006 | B2 |
7025746 | Tal | Apr 2006 | B2 |
7030904 | Adair et al. | Apr 2006 | B2 |
7041098 | Farley et al. | May 2006 | B2 |
7042487 | Nakashima | May 2006 | B2 |
7044135 | Lesh | May 2006 | B2 |
7052493 | Vaska et al. | May 2006 | B2 |
7090683 | Brock et al. | Aug 2006 | B2 |
7118566 | Jahns | Oct 2006 | B2 |
7156845 | Mulier et al. | Jan 2007 | B2 |
7163534 | Brucker et al. | Jan 2007 | B2 |
7166537 | Jacobsen et al. | Jan 2007 | B2 |
7169144 | Hoey et al. | Jan 2007 | B2 |
7186214 | Ness | Mar 2007 | B2 |
7207984 | Farr et al. | Apr 2007 | B2 |
7217268 | Eggers et al. | May 2007 | B2 |
7242832 | Carlin et al. | Jul 2007 | B2 |
7247155 | Hoey et al. | Jul 2007 | B2 |
7261711 | Mulier et al. | Aug 2007 | B2 |
7263397 | Hauck et al. | Aug 2007 | B2 |
7276061 | Schaer et al. | Oct 2007 | B2 |
7309328 | Kaplan et al. | Dec 2007 | B2 |
7416552 | Paul et al. | Aug 2008 | B2 |
7435248 | Taimisto et al. | Oct 2008 | B2 |
7527625 | Knight et al. | May 2009 | B2 |
7534204 | Starksen et al. | May 2009 | B2 |
7569052 | Phan et al. | Aug 2009 | B2 |
7736347 | Kaplan et al. | Jun 2010 | B2 |
7758499 | Adler | Jul 2010 | B2 |
7860555 | Saadat | Dec 2010 | B2 |
7860556 | Saadat | Dec 2010 | B2 |
8050746 | Saadat et al. | Nov 2011 | B2 |
8078266 | Saadat et al. | Dec 2011 | B2 |
8131350 | Saadat et al. | Mar 2012 | B2 |
8137333 | Saadat et al. | Mar 2012 | B2 |
8333012 | Rothe et al. | Dec 2012 | B2 |
20010005789 | Root et al. | Jun 2001 | A1 |
20010020126 | Swanson et al. | Sep 2001 | A1 |
20010031912 | Adler | Oct 2001 | A1 |
20010039416 | Moorman et al. | Nov 2001 | A1 |
20010047136 | Domanik et al. | Nov 2001 | A1 |
20010047184 | Connors | Nov 2001 | A1 |
20010052930 | Adair et al. | Dec 2001 | A1 |
20020004644 | Koblish | Jan 2002 | A1 |
20020026145 | Bagaoisan et al. | Feb 2002 | A1 |
20020054852 | Cate | May 2002 | A1 |
20020065455 | Ben-Haim et al. | May 2002 | A1 |
20020068853 | Adler et al. | Jun 2002 | A1 |
20020080248 | Adair et al. | Jun 2002 | A1 |
20020087166 | Brock et al. | Jul 2002 | A1 |
20020087169 | Brock et al. | Jul 2002 | A1 |
20020091304 | Ogura et al. | Jul 2002 | A1 |
20020138088 | Nash et al. | Sep 2002 | A1 |
20020165598 | Wahr et al. | Nov 2002 | A1 |
20020169377 | Khairkhahan et al. | Nov 2002 | A1 |
20030009085 | Arai et al. | Jan 2003 | A1 |
20030035156 | Cooper | Feb 2003 | A1 |
20030036698 | Kohler et al. | Feb 2003 | A1 |
20030069593 | Tremulis et al. | Apr 2003 | A1 |
20030120142 | Dubuc et al. | Jun 2003 | A1 |
20030130572 | Phan et al. | Jul 2003 | A1 |
20030144657 | Bowe et al. | Jul 2003 | A1 |
20030171741 | Ziebol et al. | Sep 2003 | A1 |
20030181939 | Bonutti | Sep 2003 | A1 |
20030208222 | Zadno-Azizi | Nov 2003 | A1 |
20030212394 | Pearson et al. | Nov 2003 | A1 |
20030216720 | Sinofsky | Nov 2003 | A1 |
20030220574 | Markus et al. | Nov 2003 | A1 |
20030222325 | Jacobsen et al. | Dec 2003 | A1 |
20040006333 | Arnold et al. | Jan 2004 | A1 |
20040049211 | Tremulis et al. | Mar 2004 | A1 |
20040054335 | Lesh et al. | Mar 2004 | A1 |
20040054389 | Osypka | Mar 2004 | A1 |
20040082833 | Adler | Apr 2004 | A1 |
20040097788 | Mourlas et al. | May 2004 | A1 |
20040117032 | Roth | Jun 2004 | A1 |
20040133113 | Krishnan | Jul 2004 | A1 |
20040138707 | Greenhalgh | Jul 2004 | A1 |
20040147806 | Adler | Jul 2004 | A1 |
20040147911 | Sinofsky | Jul 2004 | A1 |
20040147912 | Sinofsky | Jul 2004 | A1 |
20040147913 | Sinofsky | Jul 2004 | A1 |
20040158143 | Flaherty et al. | Aug 2004 | A1 |
20040158289 | Girouard et al. | Aug 2004 | A1 |
20040167503 | Sinofsky | Aug 2004 | A1 |
20040181237 | Forde et al. | Sep 2004 | A1 |
20040199052 | Banik et al. | Oct 2004 | A1 |
20040210239 | Nash et al. | Oct 2004 | A1 |
20040215180 | Starkebaum et al. | Oct 2004 | A1 |
20040215183 | Hoey et al. | Oct 2004 | A1 |
20040220471 | Schwartz | Nov 2004 | A1 |
20040230131 | Kassab et al. | Nov 2004 | A1 |
20040248837 | Raz et al. | Dec 2004 | A1 |
20040249367 | Saadat et al. | Dec 2004 | A1 |
20040254523 | Fitzgerald et al. | Dec 2004 | A1 |
20040260182 | Zuluaga et al. | Dec 2004 | A1 |
20050014995 | Amundson et al. | Jan 2005 | A1 |
20050015048 | Chiu et al. | Jan 2005 | A1 |
20050020914 | Amundson et al. | Jan 2005 | A1 |
20050027163 | Chin et al. | Feb 2005 | A1 |
20050038419 | Arnold et al. | Feb 2005 | A9 |
20050059862 | Phan | Mar 2005 | A1 |
20050059954 | Constantz | Mar 2005 | A1 |
20050059965 | Eberl et al. | Mar 2005 | A1 |
20050065504 | Melsky et al. | Mar 2005 | A1 |
20050090818 | Pike, Jr. et al. | Apr 2005 | A1 |
20050096643 | Brucker et al. | May 2005 | A1 |
20050101984 | Chanduszko et al. | May 2005 | A1 |
20050107736 | Landman et al. | May 2005 | A1 |
20050119523 | Starksen et al. | Jun 2005 | A1 |
20050124969 | Fitzgerald et al. | Jun 2005 | A1 |
20050131401 | Malecki et al. | Jun 2005 | A1 |
20050154252 | Sharkey et al. | Jul 2005 | A1 |
20050158899 | Jacobsen et al. | Jul 2005 | A1 |
20050159702 | Sekiguchi et al. | Jul 2005 | A1 |
20050165279 | Adler et al. | Jul 2005 | A1 |
20050165391 | Maguire et al. | Jul 2005 | A1 |
20050165466 | Morris et al. | Jul 2005 | A1 |
20050182465 | Ness | Aug 2005 | A1 |
20050197530 | Wallace et al. | Sep 2005 | A1 |
20050197623 | Leeflang et al. | Sep 2005 | A1 |
20050215895 | Popp et al. | Sep 2005 | A1 |
20050222557 | Baxter et al. | Oct 2005 | A1 |
20050222558 | Baxter et al. | Oct 2005 | A1 |
20050228452 | Mourlas et al. | Oct 2005 | A1 |
20050234436 | Baxter et al. | Oct 2005 | A1 |
20050234437 | Baxter et al. | Oct 2005 | A1 |
20050267328 | Blumzvig et al. | Dec 2005 | A1 |
20050267452 | Farr et al. | Dec 2005 | A1 |
20060009715 | Khairkhahan et al. | Jan 2006 | A1 |
20060009737 | Whiting et al. | Jan 2006 | A1 |
20060015096 | Hauck et al. | Jan 2006 | A1 |
20060022234 | Adair et al. | Feb 2006 | A1 |
20060025651 | Adler et al. | Feb 2006 | A1 |
20060025787 | Morales et al. | Feb 2006 | A1 |
20060030844 | Knight et al. | Feb 2006 | A1 |
20060069303 | Couvillon | Mar 2006 | A1 |
20060074398 | Whiting et al. | Apr 2006 | A1 |
20060084839 | Mourlas et al. | Apr 2006 | A1 |
20060084945 | Moll et al. | Apr 2006 | A1 |
20060089637 | Werneth et al. | Apr 2006 | A1 |
20060111614 | Saadat et al. | May 2006 | A1 |
20060122587 | Sharareh | Jun 2006 | A1 |
20060146172 | Jacobsen et al. | Jul 2006 | A1 |
20060149331 | Mann et al. | Jul 2006 | A1 |
20060155242 | Constantz | Jul 2006 | A1 |
20060161133 | Laird et al. | Jul 2006 | A1 |
20060167439 | Kalser et al. | Jul 2006 | A1 |
20060183992 | Kawashima | Aug 2006 | A1 |
20060184048 | Saadat | Aug 2006 | A1 |
20060217755 | Eversull et al. | Sep 2006 | A1 |
20060224167 | Weisenburgh et al. | Oct 2006 | A1 |
20060253113 | Arnold et al. | Nov 2006 | A1 |
20060258909 | Saadat et al. | Nov 2006 | A1 |
20060271032 | Chin et al. | Nov 2006 | A1 |
20070005019 | Okishige | Jan 2007 | A1 |
20070015964 | Eversull et al. | Jan 2007 | A1 |
20070016130 | Leeflang et al. | Jan 2007 | A1 |
20070043338 | Moll et al. | Feb 2007 | A1 |
20070043413 | Eversull et al. | Feb 2007 | A1 |
20070049923 | Jahns | Mar 2007 | A1 |
20070055142 | Webler | Mar 2007 | A1 |
20070078451 | Arnold et al. | Apr 2007 | A1 |
20070083187 | Eversull et al. | Apr 2007 | A1 |
20070083217 | Eversull et al. | Apr 2007 | A1 |
20070093808 | Mulier et al. | Apr 2007 | A1 |
20070100241 | Adler | May 2007 | A1 |
20070100324 | Tempel et al. | May 2007 | A1 |
20070106146 | Altmann et al. | May 2007 | A1 |
20070106214 | Gray et al. | May 2007 | A1 |
20070106287 | O'Sullivan | May 2007 | A1 |
20070135826 | Zaver et al. | Jun 2007 | A1 |
20070167801 | Webler et al. | Jul 2007 | A1 |
20070167828 | Saadat | Jul 2007 | A1 |
20070265609 | Thapliyal et al. | Nov 2007 | A1 |
20070265610 | Thapliyal et al. | Nov 2007 | A1 |
20070270686 | Ritter et al. | Nov 2007 | A1 |
20070282371 | Lee et al. | Dec 2007 | A1 |
20070287886 | Saadat | Dec 2007 | A1 |
20070293724 | Saadat et al. | Dec 2007 | A1 |
20080009747 | Saadat et al. | Jan 2008 | A1 |
20080009859 | Auth et al. | Jan 2008 | A1 |
20080015563 | Hoey et al. | Jan 2008 | A1 |
20080015569 | Saadat et al. | Jan 2008 | A1 |
20080027464 | Moll et al. | Jan 2008 | A1 |
20080033241 | Peh et al. | Feb 2008 | A1 |
20080033290 | Saadat et al. | Feb 2008 | A1 |
20080057106 | Erickson et al. | Mar 2008 | A1 |
20080058590 | Saadat et al. | Mar 2008 | A1 |
20080058591 | Saadat et al. | Mar 2008 | A1 |
20080058650 | Saadat et al. | Mar 2008 | A1 |
20080058836 | Moll et al. | Mar 2008 | A1 |
20080097476 | Peh et al. | Apr 2008 | A1 |
20080183081 | Lys et al. | Jul 2008 | A1 |
20080188759 | Saadat et al. | Aug 2008 | A1 |
20080214889 | Saadat et al. | Sep 2008 | A1 |
20080228032 | Starksen et al. | Sep 2008 | A1 |
20080275300 | Rothe et al. | Nov 2008 | A1 |
20080281293 | Peh et al. | Nov 2008 | A1 |
20080287790 | Li | Nov 2008 | A1 |
20080287805 | Li | Nov 2008 | A1 |
20090030276 | Saadat et al. | Jan 2009 | A1 |
20090030412 | Willis et al. | Jan 2009 | A1 |
20090054803 | Saadat et al. | Feb 2009 | A1 |
20090062790 | Malchano et al. | Mar 2009 | A1 |
20090076489 | Welches et al. | Mar 2009 | A1 |
20090076498 | Saadat et al. | Mar 2009 | A1 |
20090082623 | Rothe et al. | Mar 2009 | A1 |
20090125022 | Saadat et al. | May 2009 | A1 |
20090143640 | Saadat et al. | Jun 2009 | A1 |
20090187074 | Saadat et al. | Jul 2009 | A1 |
20090203962 | Miller et al. | Aug 2009 | A1 |
20090221871 | Peh et al. | Sep 2009 | A1 |
20090227999 | Willis et al. | Sep 2009 | A1 |
20090264727 | Markowitz et al. | Oct 2009 | A1 |
20090267773 | Markowitz et al. | Oct 2009 | A1 |
20090275799 | Saadat et al. | Nov 2009 | A1 |
20090275842 | Saadat et al. | Nov 2009 | A1 |
20090299363 | Saadat et al. | Dec 2009 | A1 |
20090326572 | Peh et al. | Dec 2009 | A1 |
20100004506 | Saadat et al. | Jan 2010 | A1 |
20100004633 | Rothe et al. | Jan 2010 | A1 |
20100004661 | Verin et al. | Jan 2010 | A1 |
20100010311 | Miller et al. | Jan 2010 | A1 |
20100094081 | Rothe et al. | Apr 2010 | A1 |
20100130836 | Malchano et al. | May 2010 | A1 |
20110060227 | Saadat | Mar 2011 | A1 |
20110060298 | Saadat | Mar 2011 | A1 |
20110144576 | Rothe et al. | Jun 2011 | A1 |
20110306833 | Saadat et al. | Dec 2011 | A1 |
20120004544 | Saadat et al. | Jan 2012 | A9 |
20120004577 | Saadat et al. | Jan 2012 | A1 |
20120016221 | Saadat et al. | Jan 2012 | A1 |
20120059366 | Drews et al. | Mar 2012 | A1 |
20120150046 | Watson et al. | Jun 2012 | A1 |
Number | Date | Country |
---|---|---|
10028155 | Dec 2000 | DE |
0283661 | Sep 1988 | EP |
0301288 | Feb 1999 | EP |
59093413 | May 1984 | JP |
59-181315 | Oct 1984 | JP |
01-221133 | Sep 1989 | JP |
03-284265 | Dec 1991 | JP |
05-103746 | Apr 1993 | JP |
09-051897 | Feb 1997 | JP |
11-299725 | Nov 1999 | JP |
2001-258822 | Sep 2001 | JP |
WO 9221292 | Dec 1992 | WO |
WO 9407413 | Apr 1994 | WO |
WO 9503843 | Feb 1995 | WO |
WO 9818388 | May 1998 | WO |
WO 03039350 | May 2003 | WO |
WO 03053491 | Jul 2003 | WO |
WO 03101287 | Dec 2003 | WO |
WO 2004043272 | May 2004 | WO |
WO 2004080508 | Sep 2004 | WO |
WO 2005070330 | Aug 2005 | WO |
WO 2005077435 | Aug 2005 | WO |
WO 2005081202 | Sep 2005 | WO |
WO 2006017517 | Feb 2006 | WO |
WO 2006024015 | Mar 2006 | WO |
WO 2006083794 | Aug 2006 | WO |
WO 2006091597 | Aug 2006 | WO |
WO 2006126979 | Nov 2006 | WO |
WO 2007067323 | Jun 2007 | WO |
WO 2007079268 | Jul 2007 | WO |
WO 2007133845 | Nov 2007 | WO |
WO 2007134258 | Nov 2007 | WO |
WO 2008015625 | Feb 2008 | WO |
WO 2008021994 | Feb 2008 | WO |
WO 2008021997 | Feb 2008 | WO |
WO 2008021998 | Feb 2008 | WO |
WO 2008024261 | Feb 2008 | WO |
WO 2008079828 | Jul 2008 | WO |
WO 2009112262 | Sep 2009 | WO |
Entry |
---|
U.S. Appl. No. 11/259,498, filed Oct. 25, 2005 in the name of Saadat, Notice of Allowance mailed Nov. 15, 2010. |
U.S. Appl. No. 11/560,732, filed Nov. 16, 2006 in the name of Saadat, Notice of Allowance mailed Feb. 3, 2011. |
U.S. Appl. No. 11/560,742, filed Nov. 16, 2006 in the name of Saadat, Notice of Allowance mailed Nov. 15, 2010. |
U.S. Appl. No. 12/464,800, filed May 12, 2009 in the name of Peh et al., non-final Office Action mailed Nov. 24, 2010. |
U.S. Appl. No. 11/848,429 filed Aug. 31, 2007 in the name of Peh et al., non-final Office Action mailed Nov. 24, 2010. |
European Patent Application No. 07812146.4 filed Jun. 14, 2007 in the name of Voyage Medical, Inc., European Search Report mailed Nov. 18, 2010. |
European Patent Application No. 07799466.3 filed Jul. 10, 2007 in the name of Voyage Medical, Inc., European Search Report mailed Nov. 18, 2010. |
U.S. Appl. No. 12/117,655, filed May 8, 2008 in the name of Peh et al., non-final Office Action mailed Dec. 16, 2010. |
U.S. Appl. No. 12/026,455, filed Feb. 5, 2008 in the name of Saadat et al., non-final Office Action mailed Dec. 27, 2010. |
U.S. Appl. No. 11/848,429, filed Aug. 31, 2007 in the name of Peh et al., non-final Office Action mailed Nov. 24, 2010. |
U.S. Appl. No. 11/775,771, filed Jul. 10, 2007 in the name of Saadat et al., Non-final Office Action mailed Aug. 27, 2010. |
U.S. Appl. No. 11/828,267, filed Jul. 25, 2007 in the name of Saadat et al., final Office Action mailed Sep. 16, 2010. |
Avitall, A Catheter System to Ablate Atrial Fibrillation in a Sterile Pericarditis Dog Model, PACE, vol. 17, p. 774, 1994. |
Avitall, Right-Sided Driven Atrial Fibrillation in a Sterile Pericarditis Dog Model, PACE, vol. 17, p. 774, 1994. |
Avitall, Vagally Mediated Atrial Fibrillation in a Dog Model can be Ablated by Placing Linear Radiofrequency Lesions at the Junction of the Right Atrial Appendage and the Superior Vena Cava, PACE, vol. 18, p. 857, 1995. |
Baker, Nonpharmacologic Approaches to the Treatment of Atrial Fibrillation and Atrial Flutter, J. Cardiovasc. Electrophysiol., vol. 6, pp. 972-978, 1995. |
Bhakta, Principles of Electroanatomic Mapping, Indian Pacing & Electrophysiol J., vol. 8, No. 1, pp. 32-50, 2008. |
Bidoggia, Transseptal Left Heart Catheterization: Usefulness of the Intracavitary Electrocardiogram in the Localization of the Fossa Ovalis, Cathet Cardiovasc Diagn., vol. 24, No. 3, pp. 221-225, 1991. |
Bredikis, Surgery of Tachyarrhythmia: Intracardiac Closed Heart Cryoablation, PACE, vol. 13, pp. 1980-1984, 1990. |
Cox, Cardiac Surgery for Arrhythmias, J. Cardiovasc. Electrophysiol., vol. 15, pp. 250-262, 2004. |
Cox, Five-Year Experience With the Maze Procedure for Atrial Fibrillation, Ann. Thorac. Surg., vol. 56, pp. 814-824, 1993. |
Cox, Modification of the Maze Procedure for Atrial Flutter and Atrial Fibrillation, J. Thorac. Cardiovasc. Surg., vol. 110, pp. 473-484, 1995. |
Cox, The Status of Surgery for Cardiac Arrhythmias, Circulation, vol. 71, pp. 413-417, 1985. |
Cox, The Surgical Treatment of Atrial Fibrillation, J. Thorac Cardiovasc. Surg., vol. 101, pp. 584-592, 1991. |
Elvan, Replication of the “Maze” Procedure by Radiofrequency Catheter Ablation Reduces the Ability to Induce Atrial Fibrillation, PACE, vol. 17, p. 774, 1994. |
Elvan, Radiofrequency Catheter Ablation (RFCA) of the Atria Effectively Abolishes Pacing Induced Chronic Atrial Fibrillation, PACE, vol. 18, p. 856, 1995. |
Elvan, Radiofrequency Catheter Ablation of the Atria Reduces Inducibility and Duration of Atrial Fibrillation in Dogs, Circulation, vol. 91, pp. 2235-2244, 1995. |
European Patent Application No. 06734083.6 filed Jan. 30, 2006 in the name of Saadat et al., extended European Search Report mailed Jul. 1, 2009. |
European Patent Application No. 06734083.6 filed Jan. 30, 2006 in the name of Saadat et al., office action mailed Oct. 23, 2009. |
Fieguth, Inhibition of Atrial Fibrillation by Pulmonary Vein Isolation and Auricular Resection—Experimental Study in a Sheep Model, European J. Cardiothorac. Surg., vol. 11, pp. 714-721, 1997. |
Hoey, Intramural Ablation Using Radiofrequency Energy Via Screw-Tip Catheter and Saline Electrode, PACE, vol. 18, p. 487, 1995. |
Huang, Increase in the Lesion Size and Decrease in the Impedance Rise with a Saline Infusion Electrode Catheter for Radiofrequency, Circulation, vol. 80, No. 4, pp. II-324, 1989. |
Moser, Angioscopic Visualization of Pulmonary Emboli, CHEST, vol. 77, No. 2, pp. 198-201, 1980. |
Nakamura, Percutaneous Intracardiac Surgery With Cardioscopic Guidance, SPIE, vol. 1652, pp. 214-216, 1992. |
Pappone, Circumferential Radiofrequency Ablation of Pulmonary Vein Ostia, Circulation, vol. 102, pp. 2619-2628, 2000. |
Sethi, Transseptal Catheterization for the Electrophysiologist: Modification with a “View”, J. Interv. Card. Electrophysiol., vol. 5, pp. 97-99, 2001, Kluwer Academic Publishers, Netherlands. |
Thiagalingam, Cooled Needle Catheter Ablation Creates Deeper and Wider Lesions than Irrigated Tip Catheter Ablation, J. Cardiovasc. Electrophysiol., vol. 16, pp. 1-8, 2005. |
U.S. Appl. No. 11/259,498, filed Oct. 25, 2005 in the name of Saadat et al., Non-final Office Action mailed Feb. 25, 2010. |
U.S. Appl. No. 11/828,267, filed Jul. 25, 2007 in the name of Saadat et al., Non-final Office Action mailed Jan. 14, 2010. |
U.S. Appl. No. 12/117,655, filed May 8, 2008 in the name of Saadat et al., Non-final Office Action mailed Jun. 8, 2009. |
U.S. Appl. No. 61/286,283, filed Dec. 14, 2009 in the name of Rothe et al. |
U.S. Appl. No. 61/297,462, filed Jan. 22, 2010 in the name of Rothe et al. |
Uchida, Developmental History of Cardioscopes, Coronary Angioscopy, pp. 187-197, 2001, Future Publishing Co., Armonk, NY. |
Willkampf, Radiofrequency Ablation with a Cooled Porous Electrode Catheter, JACC, vol. 11, No. 2, p. 17A, 1988. |
European Patent Application No. 06734083.6 filed Jan. 30, 2006 in the name of Voyage Medical, Inc., Office Action mailed Nov. 12, 2010. |
U.S. Appl. No. 12/947,198, filed Nov. 16, 2010 in the name of Saadat, non-final Office Action mailed Feb. 18, 2011. |
U.S. Appl. No. 12/947,246, filed Nov. 16, 2006 in the name of Saadat, non-final Office Action mailed Feb. 18, 2011. |
U.S. Appl. No. 11/687,597, filed Mar. 16, 2007 in the name of Saadat, Notice of Allowance mailed Feb. 24, 2011. |
U.S. Appl. No. 11/560,732, filed Mar. 16, 2007 in the name of Saadat, Notice of Allowance mailed Feb. 24, 2011. |
U.S. Appl. No. 11/848,207, filed Aug. 30, 2007 in the name of Saadat et al., non-final Office Action mailed Feb. 25, 2011. |
Japanese Patent Application No. 2007-554156 filed Jan. 30, 2006 in the name of Voyage Medical, Inc., Office Action mailed Feb. 15, 2011. |
European Patent Application No. 07758716.0 filed Mar. 16, 2007 in the name of Voyage Medical, Inc., Supplemental European Search Report mailed Feb. 28, 2011. |
U.S. Appl. No. 11/848,202, filed Aug. 30, 2007 in the name of Saadat et al., non-final Office Action mailed Mar. 11, 2011. |
U.S. Appl. No. 11/763,399, filed Jun. 14, 2007 in the name of Saadat et al., non-final Office Action mailed Apr. 11, 2011. |
U.S. Appl. No. 12/499,011, filed Jul. 7, 2009 in the name of Rothe et al., non-final Office Action mailed Apr. 12, 2011. |
U.S. Appl. No. 12/367,019, filed Feb. 6, 2009 in the name of Miller et al., non-final Office Action mailed Apr. 22, 2011. |
U.S. Appl. No. 11/959,158, filed Dec. 18, 2007 in the name of Saadat et al., non-final Office Action mailed Apr. 25, 2011. |
U.S. Appl. No. 11/848,532, filed Aug. 31, 2007 in the name of Saadat et al., non-final Office Action mailed Apr. 26, 2011. |
U.S. Appl. No. 11/828,281, filed Jul. 25, 2007 in the name of Peh et al., non-final Office Action mailed Apr. 27, 2011. |
U.S. Appl. No. 11/961,950, filed Dec. 20, 2007 in the name of Saadat et al., non-final Office Action mailed May 9, 2011. |
U.S. Appl. No. 11/961,995, filed Dec. 20, 2007 in the name of Saadat et al., non-final Office Action mailed May 9, 2011. |
U.S. Appl. No. 11/962,029, filed Dec. 20, 2007 in the name of Saadat et al., non-final Office Action mailed May 9, 2011. |
U.S. Appl. No. 11/828,267, filed Jul. 25, 2007 in the name of Saadat et al., non-final Office Action mailed May 11, 2011. |
Japanese Patent Application No. 2009-500630 filed Mar. 16, 2007 in the name of Voyage Medical, Inc., Office Action mailed Apr. 27, 2011. |
U.S. Appl. No. 11/775,771, filed Jul. 10, 2007 in the name of Saadat et al., final Office Action mailed May 12, 2011. |
U.S. Appl. No. 11/877,386, filed Oct. 23, 2007 in the name of Saadat et al., non-final Office Action mailed May 20, 2011. |
U.S. Appl. No. 11/775,819, filed Jul. 10, 2007 in the name of Saadat et al., non-final Office Action mailed May 20, 2011. |
U.S. Appl. No. 11/775,837, filed Jul. 10, 2007 in the name of Saadat et al., non-final Office Action mailed May 23, 2011. |
U.S. Appl. No. 12/117,655, filed May 8, 2008 in the name of Peh et al., final Office Action mailed Jun. 2, 2011. |
U.S. Appl. No. 12/323,281, filed Nov. 25, 2008 in the name of Saadat et al., non-final Office Action mailed Jun. 7, 2011. |
Japanese Patent Application No. 2007-554156 filed Jan. 30, 2006 in the name of Voyage Medical, Inc., Notice of Allowance mailed Jun. 13, 2011. |
European Patent Application No. 06734083.6 filed Jan. 30, 2006 in the name of Saadat et al., Examination Communication mailed May 18, 2010. |
European Patent Application No. 07841754.0 filed Aug. 31, 2007 in the name of Saadat et al., Supplemental European Search Report mailed Jun. 30, 2010. |
European Patent Application No. 08746822.9 filed Apr. 24, 2008 in the name of Rothe et al., European Search Report mailed Mar. 29, 2010. |
European Patent Application No. 08746822.9 filed Apr. 24, 2008 in the name of Rothe et al., Office Action mailed Jul. 13, 2010. |
U.S. Appl. No. 11/560,742, filed Nov. 16, 2006 in the name of Saadat, Non-final Office Action mailed Jun. 10, 2010. |
U.S. Appl. No. 11/687,597, filed Mar. 16, 2007 in the name of Saadat et al., Non-final Office Action mailed Jul. 21, 2010. |
U.S. Appl. No. 12/117,655, filed May 8, 2008 in the name of Peh et al., Final Office Action mailed Mar. 1, 2010. |
Number | Date | Country | |
---|---|---|---|
20100292558 A1 | Nov 2010 | US | |
20130172726 A9 | Jul 2013 | US |
Number | Date | Country | |
---|---|---|---|
61177618 | May 2009 | US | |
60804801 | Jun 2006 | US | |
60806924 | Jul 2006 | US | |
60806926 | Jul 2006 | US | |
60871415 | Dec 2006 | US | |
60871424 | Dec 2006 | US | |
60888242 | Feb 2007 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11763399 | Jun 2007 | US |
Child | 12778878 | US |